Three holders that each own roughly 10% of Sionna Therapeutics Inc (NASDAQ:SION) disclosed the sale of common stock on January 22, 2026. The sellers - TPG GP A, LLC, Coulter James G, and Winkelried Jon - sold a total of 250,000 shares at $40.00 per share, producing aggregate proceeds of $10,000,000.
Following the transaction, the reporting entities continue to hold 6,494,962 shares of Sionna Therapeutics.
Analyst activity and diverging opinions
Sionna has recently been the subject of differing analyst updates. Raymond James raised its price target for the company from $45.00 to $53.00 and maintained a Strong Buy rating. The firm tied its more bullish outlook to anticipated proof-of-concept results for Sionna’s NBD1 stabilizers - specifically SION-719 and SION-451 - which it expects by mid-2026.
By contrast, RBC Capital moved to downgrade Sionna Therapeutics from Sector Perform to Underperform, while keeping a price target of $24.00. RBC Capital highlighted concerns about the company’s roughly $2 billion market capitalization and questioned the optimism built into expectations for the NBD1 stabilizers. The downgrade followed a period in which Sionna’s stock roughly doubled without what RBC characterized as commensurate fundamental developments.
Notably, despite the downgrade from RBC Capital, Raymond James reiterated its Strong Buy stance and a $45.00 price target after Sionna’s third-quarter 2025 update.
Ongoing clinical work
Sionna is actively running clinical studies. Among these is a Phase 2a proof-of-concept study testing SION-719 as an add-on to Trikafta in patients with cystic fibrosis. The company’s development program for its NBD1 stabilizers - SION-719 and SION-451 - is central to the differing analyst views described above.
This report focuses on the disclosed insider transaction and the contemporaneous analyst commentary; it does not add or infer information beyond the company-level facts and analyst positions provided.